Identifying which archetypical profile fits your patient can help oncology nurses individualize support and education needs to their patients.
As molecular testing becomes the standard of care for many cancers, nurse navigators have an important role to play ensuring molecular testing of suitable patients, providing patient education, and managing of patient expectations.
Precision Medicine Improves Pancreatic Cancer Treatment
The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
A personalized testing method may quickly and more accurately predict the effectiveness of a treatment for multiple myeloma in individual patients. The process may also aid patients with leukemia or lymphoma.
Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
Eight of 14 patients in the first clinical trial of personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing beyond 4.5 years.
Researchers developed a way to personalize treatments for aggressive bladder cancer. Taking bladder tumors from individual patients, identifying actionable mutations, and grafting the tumors into mice, researchers were able to simultaneously test multiple therapies in the tumor models.
Results are in from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.
Researchers examined patient participation in the genomic analysis portion of clinical trials.
An increased understanding of how a certain tumor suppressor molecule works to prevent tumor growth may open the door to a personalized treatment approach for colon cancer.
New research indicates that many genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the person.
An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.
Adrenal cancer is among the more rare and aggressive forms of cancer, but new research indicates the possibility of personalized treatment.
A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.
The use of 3D printing to construct devices of varied sizes and shapes could become a powerful tool in customizing interventional radiology treatments to individual patient needs.
New animal models have been developed that allow for improved parallel tumor progression and can help clinicians predict relapses and treatment effectiveness.
Pediatric patients with acute lymphoblastic leukemia (ALL) showed a 90% response rate from the first trials testing an investigational personalized cellular therapy known as CTL019.
The possibilities for personalized vaccines in all types of cancer were explored at the European Society for Medical Oncology Symposium on Immuno-Oncology 2014.
A genetic test has been developed to identify which men are at higher risk for prostate cancer recurrence after localized treatment with surgery or radiotherapy.
Circulating tumor cells captured with a microchip-based device can be cultured to establish cell lines for genetic analysis and drug testing.
The era of personalized medicine for breast cancer may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School.
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
Researchers have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients.
With accelerating development of personalized cancer treatments matched to a patient's DNA sequencing, proponents of these treatments say frontline physicians increasingly need help finding the best individualized therapy.
In a new study, researchers examined the largest collection of tumor samples to date to predict patient-specific tumor mutations that may activate the patient's immune system, paving the way for more successful, personalized cancer immunotherapy.
A new predictive tool is being developed that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help.
Two studies provide new insight into a germline epidermal growth factor receptor T790M mutation in familial non-small cell lung cancer, and suggest the need for tailored approaches for early detection and treatment.
Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a proof-of-concept study.
Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- A Witness to Letting Go: Nursing Care at the End of Life
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|